Global Non-Invasive Diabetes Therapy Market - 2024 - 2031

Report Overview

The Global Non-Invasive Diabetes Therapy Market reached US$ 245.3 million in 2023 and is expected to reach US$ 446.1 million by 2031, growing at a CAGR of 7.9% during the forecast period 2024-2031.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood glucose. Hyperglycaemia, also called raised blood glucose or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body's systems, especially the nerves and blood vessels.

Type 1 diabetes, also known as insulin-dependent, juvenile, or childhood-onset is characterized by deficient insulin production and requires daily administration of insulin. Type 2 diabetes affects how the body uses sugar for energy. It stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated. Over time, type 2 diabetes can cause serious damage to the body, especially nerves and blood vessels. Type 2 diabetes is often preventable. Factors that contribute to developing type 2 diabetes include being overweight, not getting enough exercise, and genetics.

A medical procedure is defined as non-invasive when no break in the skin is created and there is no contact with the mucosa, skin break, or internal body cavity beyond a natural or artificial body orifice. The non-invasive treatment is one of the most important methods involved in diabetes therapeutics.

Market Dynamics: Drivers

Increasing prevalence of diabetes

The rising prevalence of diabetes propels the market growth. For instance, according to the World Health Organization, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades.

Moreover, according to an article published by the Institute for Health Metrics and Evaluation in June 2023, The latest and most comprehensive calculations show the current global prevalence rate is 6.1%, making diabetes one of the top 10 leading causes of death and disability. At the super-region level, the highest rate is 9.3% in North Africa and the Middle East, and that number is projected to jump to 16.8% by 2050. The rate in Latin America and the Caribbean is projected to increase to 11.3%.

Diabetes was especially evident in people 65 and older in every country and recorded a prevalence rate of more than 20% for that demographic worldwide. The highest rate was 24.4% for those between ages 75 and 79. Examining the data by super-region, North Africa and the Middle East had the highest rate at 39.4% in this age group, while Central Europe, Eastern Europe, and Central Asia had the lowest rate at 19.8%.

Restraints

Factors such as high cost associated with the products, and accuracy of monitoring are expected to hamper the market. The prices of the products that are used for diabetes are high. Since diabetes is a chronic disease, the medication must be followed for a very long time which results in a decrease in the affordability rate.

Market Segment Analysis

The global non-invasive diabetes therapy market is segmented based on product, diabetes type, end-user, and region.

The segment oral insulin accounted for approximately 56.4% of the global non-invasive diabetes therapy market share

The oral insulin segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements, and rising funds for private manufacturers for clinical trials would drive this market.

Oral insulin mimics this precise physiologic route as it is absorbed from the gastrointestinal tract into the portal vein and consequently may have salutary metabolic consequences due to the direct engagement of the liver and the resumption of its role in glucose metabolism. Furthermore, oral insulin is likely to convey additional advantages with plausible beneficial clinical ramifications, including the reduction of hyperinsulinemia, the forestalling of weight gain associated with systemic insulin therapy, and reducing the risk of hypoglycemia.

For instance, in June 2024, Dr. Shyh-Dar Li and his research team at the Li Lab developed oral insulin drops that when placed under the tongue are quickly and efficiently absorbed by the body, potentially replacing the need for insulin injections. The drops contain a mixture of insulin and a unique cell-penetrating peptide (CPP).

Market Geographical Analysis

North America accounted for approximately 42.1% of the global non-invasive diabetes therapy market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of diabetes, and technological advancements, in this region, help to propel the market.

For instance, according to the Centers for Disease Control and Prevention (CDC), in November 2023, it is estimated that, estimates that 136 million adults are living with diabetes or prediabetes in the United States. For both men and women, the prevalence of diagnosed diabetes was highest among American Indian and Alaskan Native adults (13.6%), followed by non-Hispanic Black adults (12.1%), adults of Hispanic origin (11.7%), non-Hispanic Asian adults (9.1%), and non-Hispanic White adults (6.9%). Adults with a family income above 500% of the federal poverty level had the lowest prevalence of diabetes for both men (6.3%) and women (3.9%), compared to families with a family income at or below the poverty level (13.1%).

Moreover in June 2023, The FDA approved empagliflozin (Jardiance) and empagliflozin/metformin hydrochloride (Synjardy) used with diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes.

Market Segmentation

By Product

Oral Insulin

ORMD-0801

Eligen

IN-105

Macrulin

Buccal Insulin

Oral-Lyn

Others

Ocular Insulin

Inhaled Insulin

Exubera

Afrezza

Technosphere insulin

AERx iDMS

Aerodose

Nasal Insulin

Nasulin

QDose

Others

Transdermal Insulin

Others

By Diabetes Type

Type 1

Type 2

By End-User

Hospitals

Specialty Clinics

Homecare

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global non-invasive diabetes therapy market include Oramed, Novo Nordisk A/S, Biocon, Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, AstraZeneca, Eli Lilly and Company, Novartis AG among others.

Key Developments

In January 2024, Drug firm Lupin announced that it had received approval from the US health regulator to market a generic medication to treat diabetes. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets.

In July 2024, Zydus Lifesciences received approval from the US health regulator for its new drug application for diabetes medication. The company has received final approval for its new drug application (NDA) from the US Food and Drug Administration (USFDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride).

Why Purchase the Report?

To visualize the global non-invasive diabetes therapy market segmentation based on product, diabetes type, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global non-invasive diabetes therapy market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global non-invasive diabetes therapy market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies